Challenges in rare disease development

There are around 7,000 rare diseases, which from a regulatory outlook are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Orphan drugs are medicinal products envisioned for diagnosis, prevention, and treatment of life-threatening rare diseases. They are "orphans" because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions

  • Enrolling, engaging and retaining patients
  • Designing and evaluating clinical trials
  • Ensuring the quality of patient data
  • Global regulatory requirements and payer evidence

Related Conference of Challenges in rare disease development

April 04-05, 2024

17th European Biosimilars Congress

Madrid, Spain
April 11-12, 2024

5th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
May 09-10, 2024

4th Global Summit on Pharmaceutical Research

Barcelona, Spain
May 16-17, 2024

18th World Drug Delivery Summit

Rome, Italy
May 30-31, 2024

9th Pharmaceutical Chemistry Conference

Paris, France
July 25-26, 2024

34th Annual European Pharma Congress

Frankfurt, Germany
September 11-12, 2024

9th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 25-26, 2024

4th World Congress on Rare Diseases & Orphan Drugs

Paris, France
November 26-27, 2024

3rd World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2024

3rd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 28-29, 2024

39th World Congress on Pharmacology and Therapeutics

Paris, France
November 28-29, 2024

12th International Conference on Clinical Trials

Vancouver, Canada
December 05-06, 2024

17th World Drug Delivery Summit

Dubai, UAE

Challenges in rare disease development Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in